ANTAGONIST DRUGS. “Elevated local or systemic IL-1β has been linked to a number of human hereditary or acquired diseases, and antagonists of IL-1β or its receptor are proving successful treatments for a number of these diseases. Clinical trials are currently assessing efficacy of Anakinra and next-generation IL-1β inhibitors for a wider range of diseases, including cryopyrin-associated periodic syndromes (CAPS), gout, and type II diabetes.”
http://www.sciencedirect.com/science/article/pii/S0092867410000759
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022